Change in Number of Shares and Votes in Moberg Pharma

STOCKHOLM--()--Regulatory News:

Moberg Pharma (STO:MOB)

The number of shares and votes in Moberg Pharma AB (publ) has increased by 215,985 to 14,217,522 during December 2015. Therefore, there are in total 14,217,522 shares and votes in the company as of July 31, 2015.

The reason for the increase is that warrants in Moberg Pharma have been exercised under the company’s share-based incentive program.

About Moberg Pharma, www.mobergpharma.com

Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with OTC sales operations in the U.S. and a distributor network in more than 40 countries. The company’s portfolio includes the OTC brands Kerasal®, Kerasal Nail®, Balmex®, Domeboro®, Jointflex®, Vanquish®, and Fergon®. Kerasal Nail®(Emtrix®or Nalox™ in certain markets) is a leading OTC treatment of nail disorders in the U.S., Canada and several EU markets and is currently being launched in Southeast Asia. The company is growing organically as well as through acquisitions. Internal development programs focus on innovative drug delivery of proven compounds and include two clinical stage assets, MOB-015 (onychomycosis) and BUPI (pain management in oral mucositis). Moberg Pharma has offices in Stockholm and New Jersey and the company’s shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).

About this information

Moberg Pharma discloses this information pursuant to the Swedish Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 8.30 a.m. (CET) on December 30, 2015.

This information was brought to you by Cision http://news.cision.com

Contacts

Moberg Pharma
Peter Wolpert
CEO
Telephone: +46 (0)70 - 735 7135
E-mail: peter.wolpert@mobergpharma.se
or
Anna Ljung
CFO
Telephone: +46 (0)70 - 766 60 30
E-mail: anna.ljung@mobergpharma.se

Contacts

Moberg Pharma
Peter Wolpert
CEO
Telephone: +46 (0)70 - 735 7135
E-mail: peter.wolpert@mobergpharma.se
or
Anna Ljung
CFO
Telephone: +46 (0)70 - 766 60 30
E-mail: anna.ljung@mobergpharma.se